RESEARCH Open Access

(2019) 20:29

Detection of some metabolic disorders in suspected neonates admitted at Assiut University Children Hospital



Shaimaa Mohamed Khalaf^{1*}, Mohamed Mahrous El-Tellawy¹, Nafisa Hassan Refat¹ and Amal Mohammed Abd El-Aal²

Abstract

Background: Inborn errors of metabolism are genetically inherited diseases which can lead to accumulation of toxic metabolites in the body. Inborn errors of metabolism have a high morbidity and mortality in neonates. Many inborn errors of metabolism are amenable to treatment with early diagnoses. Till now, more than 500 metabolic disorders have been detected. Although individual metabolic disorders are rare, the incidence of overall metabolic disorders is high.

Results: It was found that 70/200 cases (35 %) had confirmed inborn errors of metabolism, and another 8 cases (4%) suspected to have inborn errors of metabolism; 15/200 (7.5%) cases had mild elevation of phenylalanine level, while 107/200 (53.5%) had another diagnosis rather than metabolic disorders. Urea cycle defect was diagnosed in 20/70 (28.5%), maple syrup urine disease in 18/70 (25.7%), organic acidemia in 15/70 (21.4%), and non-ketotic hyperglycinemia in 1/70 (1.4%) case. Also, 15/70 (21.4%) cases had fatty acid oxidation defect. Lastly, one female case (1.4%) was diagnosed to have disorder of pyrimidine deficiency.

Conclusion: Diagnosis of inborn errors of metabolism was confirmed in 35% of neonates, and 4% was suspected to have metabolic disorders. These results showed that inherited metabolic disorders are not rare. The development of a nationwide screening program for metabolic disorders is mandatory for early detection of these potentially treatable disorders.

Keywords: Neonatal screening, Inborn errors of metabolism (IEM), Metabolic disorders, Aminoacidopathies, Fatty acid oxidation defects, Tandem mass spectrometry

Background

Inborn errors of metabolism (IEM) are a group of inherited genetic metabolic disorders that lead to enzymatic defects in the human metabolism and form a large class of genetic diseases. The cause of IEM is the mutation in a gene that encodes for an enzyme, leading to defective synthesis of this enzyme or its activity. This affects the normal function of a metabolic pathway. In most disorders, problems arise from accumulation of substrates which are toxic to tissues, organs, or blood [1].

Till now, more than 500 IEMs have been detected. Although individual IEM is rare, the incidence of overall IEMs is high and varies dramatically in different countries and regions [2]. According to the Society for the Study of Inborn Errors of Metabolism (SSIEM) [1] and based on the main substrate, which is affected, IEM was classified as follows:

- Disorders of amino acid (e.g., maple syrup urine disease, organic acidemias, and urea cycle defects)
- Disorders of carbohydrate metabolism (e.g., galactosemia and glycogen storage disorders)
- Disorder of lipid metabolism (e.g., fatty acid oxidation defects [medium chain acyl-CoA dehydrogenase deficiency])

Full list of author information is available at the end of the article



^{*} Correspondence: DrShymaaKhalaf@Gmail.com

¹Pediatrics, Assiut University, Assiut University Children Hospital, Assiut 71515,

• Disorders in the metabolism of purines and pyrimidines

Many IEMs are amenable to treatment with early diagnoses. For others that are not amenable to treatment, establishing diagnosis in the index case is important for prenatal diagnosis in subsequent pregnancy [3].

• Early diagnosis and treatment are very important to reduce the rates of morbidity and mortality related to IEMs. The first step is suspicion, followed by performing routine and specific laboratory analysis as soon as possible. Early neonatal screening is important especially in countries with high rates of consanguinity because early diagnosis and treatment are likely to result in better neurodevelopmental outcomes and lower mortality rates.

The study aimed for:

- Early detection, diagnosis, and intervention to improve the neonatal outcome
- Emphasizing the importance of expanded early neonatal screening

Methods

The study included 200 cases out of 5500 neonates admitted to Neonatal Intensive Care Unit. The study was conducted in the period from January 2015 to June 2018.

Inclusion criteria

- Positive family history with affected siblings or unexplained infant/neonatal death
- Persistent unexplained vomiting
- Persistent metabolic acidemia
- Convulsions
- Hypoglycemia
- Respiratory distress or apnea
- Drowsiness or disturbed consciousness level

• Poor oral intake and dehydration

Exclusion criteria

- Multiple congenital anomalies
- Birth anoxia
- Birth trauma
- Neonates with intracranial hemorrhage
- Neonates with surgical problem
- Neonatal sepsis based on clinical and laboratory finding

All the studied cases were subjected to (1) history taking provided by the care-giver: assessment of the following factors—sex, birth weight, gestational age, and consanguinity. The suggestive complaints of IEM were poor suckling, weak crying, convulsions, persistent vomiting, lethargy, previous sibling deaths, persistent metabolic acidosis, hypoglycemia, and/or hyperammonemia. (2) Full clinical examination: general, abdominal, cardiac, chest, and neurological examination. (3) Laboratory investigations include routine investigations (complete blood picture, C-reactive protein (CRP), liver function tests, renal function tests, serum ammonia, serum lactate, arterial blood gas, and serum glucose level), and specific metabolic investigation includes metabolic screen in blood and organic acid in urine.

Mass spectrometry analysis

Whole blood samples were drawn by heel prick or venipuncture from high-risk babies and spotted on Whatman 903 filter paper (Whatman Inc., USA). Amino acids and acylcarnitines were analyzed using a triple-quadrupole mass spectrometer, equipped with a (Acqulity, Water, USA) Waters Alliance 2790 HPLC pump.

The result of MS/MS includes levels of tyrosine, phenylalanine, citrulline, alanine, methionine, proline, leucine/isoleucine, arginine, valine, glycine, glutamic acid, aspartic acid, and argininosuccinic acid, and 29 acylcarnitines—C0, C2, C3, C3-DC, C4, C4-DC, C4-OH, C5, C5:1, C5-DC, C5-OH, C6, C6-DC, C6-OH, C8, C8-OH, C10, C10:1,

Table 1 Socio-demographic characteristics of the studied cases

Variable	Category	n = 200
Gestational age/weeks	• Mean ± SD (range)	37.26 ± 1.3 (36–39)
Gestational age Category	• Pre-term (< 37 weeks)	36 (18%)
	• Full-term (> 37 weeks)	164 (82%)
Sex	• Female	78 (39%)
	• Male	122 (61%)
Consanguinity	• Yes	122 (61%)
Presentation day	• Mean ± SD (range)	$6.45 \pm 0.7 (3-12)$
Weight/kg	• Mean ± SD (range)	$2.64 \pm 0.7 \ (1.8-3.5)$

Table 2 Frequency of the most common manifestation among cases

cuses		
Symptoms	Poor suckling	122 (61%)
	 Respiratory distress 	114 (57%)
	 Convulsion 	108 (54%)
	 Vomiting 	104 (52%)
	 Sibling affected* 	60 (30%)
	• Disturbed conscious level	58 (29%)
Signs	 Delay capillary refill time 	44 (22%)
	 Hepatomegaly 	12 (6%)
	 Splenomegaly 	8 (4%)
	• Jaundice	108 (58%)

*Sibling affected in the affected families means that this family had another newborn that had the same manifestations and findings, and in some families, they had the same diagnosis

C12, C12:1, C14, C14:1, C14:2, C16, C16-OH, C18, C18:1, C18-OH, and C18:1-OH—were quantified. Multiple analyte ratios were also calculated as Phe/Tyr, Leu/Phe, C3/C2, and C3-DC/C10. The internal standards were purchased from Cambridge Isotope Laboratories, and the Neolynx software (Neolynx Inc., CA, USA) was used for processing MS/MS data.

Organic acids in urine

Random urine samples were taken (5 ml) by using urine collecting bag and stored at -20 °C for organic acid analysis by gas chromatography/mass spectrometry (GC/MS).

Test principle of organic acids in urine

Determination of organic acids in urine was done by GC/MS technique. Urine organic acid profile is an important second-line investigation in which up to 150 different disorders can be identified from a single analysis. However, some inborn errors of metabolism are clearly identifiable only during episodes of acute decompensation, e.g., medium chain acyl-CoA dehydrogenase deficiency.

Table 3 The difference between the commonly diagnosed cases in our study (AAD and FAOD) in relation to consanguinity, sibling affection, convulsions, DCL, vomiting, and poor suckling

		٥. ١	
	AAD (n = 54)	FAOD (n = 15)	p value*
Consanguinity	45(83%)	10 (67%)	= 0.022
Sibling affected	20 (37%)	3 (20%)	= 0.157
Convulsions	28(51%)	8 (53%)	= 0.011
DCL	18(33%)	5 (33%)	= 0.030
Vomiting	30(55%)	6 (40%)	= 0.022
Poor suckling	40 (74%)	7 (47%)	= 0.005

AAA amino acid disorder, FAOD fatty acids oxidation defect, DCL disturbed conscious level

Table 4 The difference between the commonly diagnosed cases in our study (AAD and FAOD) in relation to hypotonia, spasticity, skin manifestations, and hepatomegaly

	AAD $(n = 54)$	FAOD ($n = 15$)	P value*
Hypotonia	40 (74%)	13 (87%)	= 0.014
Spasticity	10 (18.5%)	0 (0%)	= 0.001
Skin manifestations ^{\$}	5 (9.2%)	0 (0%)	< 0.001
Hepatomegaly	0 (0%)	6 (40%)	< 0.001

AAA amino acid disorder, FAOD fatty acids oxidation defect

Gas chromatography/mass spectrometry (GC/MS) is the most reliable method for urine organic acid analysis to detect organic acidemia and other metabolic disorders.

Statistical analysis

Data were verified, coded by the researcher, and analyzed using IBM-SPSS version 19 (@IBM-SPSS Inc., 2012, NY, USA). Data were presented as number and percentage or mean \pm standard deviations. Chi-square test analysis was used to compare the proportions between qualitative variables. p value was considered statistically significant when $p \le 0.05$.

Results

The current study recruited 5500 neonates admitted to Neonatal Intensive Care Unit, in the period from January 2015 till June 2018. Highly suspected 200 cases with IEM were studied to be diagnosed.

The socio-demographic characteristics of the studied cases were 60% males (n = 122) and 78 (39%) females. Their age ranged from 1 to 30 days after birth (Table 1).

The most common manifestations of the studied cases were poor suckling (61%), followed by respiratory

Table 5 Routine screening investigations for diagnosis of the IEM of the studied patients

Variable	Category	N = 200
Blood PH analysis	• Low (acidosis)	38 (19%)
	• Normal	152 (76%)
	 High (alkalosis) 	10 (5%)
Plasma ammonia	• Normal (15–45 μmol/L)	96 (48%)
	• High (≥ 45 µmol/L)	100 (50%)
	 Not done 	4 (2%)
Plasma lactate	• Normal (10–16 mg/dl)	134 (67%)
	• High (≥ 16 mg/dl)	64 (32%)
	 Not done 	2 (1%)
Serum glucose level	• Normal (5.5–9 mmol/L)	136 (68%)
	• Low (< 5.5 mol/L)	64 (32%)

^{*}Chi-square test was used to compare the proportion difference between groups

^{*}Chi-square test was used to compare the proportion difference between groups

^{\$}Skin lesion in the form of erythema and exfoliative changes

Table 6 The difference between the commonly diagnosed cases in our study in relation to metabolic acidosis, hyperammonemia, hyperlactatemia, and hypoglycemia

	AAD $(n = 54)$	FAOD $(n = 15)$	P value*
Metabolic acidosis	23 (42.5%)	6 (40%)	< 0.011
Hyperammonemia	45(83%)	6 (40%)	< 0.002
Hyperlactatemia	43(79.6%)	10 (67%)	< 0.012
Hypoglycemia	33 (61%)	12 (80%)	< 0.003

AAA amino acid disorder, FAOD fatty acids oxidation defect *Chi-square test was used to compare the proportion difference between groups

distress (57%), then convulsions (54%) and vomiting (52%) (Tables 2, 3, 4, 5, 6, 7, and 8).

The outcome of the cases with IEM shows that 36% of them were discharged on treatment and continue follow-up at genetic unit and the rest of the cases (64%) died due to complications.

Discussion

In the current study, consanguinity was positive in 122 patients (61%) of patients. It was higher than that reported in

Table 7 The different disease types of the studied cases after routine and specific laboratory finding

Variable	n = 200
IEM	70 (35%)
1. Urea cycle defect (UCD)	20 (28.5%)
2. Maple syrup urine disease (MSUD)	18 (25.7%)
3. Fatty acid oxidation defect (FAOD)	15 (21.4%)
4. Organic acidemia (OA)	15(21.4%)
5. Hyperglycinemia (HGN)	1 (1.4 %)
6. Di-hydro-pyrimidine dehydrogenase deficiency (DHPD)	1 (1.4 %)
Suspected IEM (unconfirmed)	8 (4%)
1. Suspected tyrosinemia (ST)	4 (2%)
2. Suspected galactosemia (SG)	3 (1.5%)
3. Suspected multiple carboxylase deficiency	1 (0.5%)
Transient hyperphenylalaninemia (THPN)	15 (7.5)
Diagnosis rather than IEM	63 (31.5%)
1. Neonatal sepsis (NS)	26 (13%)
2. Hypoxic ischemic encephalopathy (HIE)	10 (5%)
3. Necrotizing entercolitis (NEC)	9 (4.5%)
4. Hyperinsulinemia (HI)	6 (3%)
5. Hypoparathyroidism (HPT)	4 (2%)
6. Congenital adrenal hyperplasia (CAH)	4 (2%)
7. Intestinal obstruction (IO)	4 (2%)
Undiagnosed	44 (22%)

UCD urea cycle defect, MSUD maple syrup urine disease, FAOD fatty acid oxidation defect, THPA transient hyperphenylalaninemia, OA organic acidemia, ST suspected tyrosinemia, SG suspected galactosemia, GA glutaric acidemia, SMCD suspected multiple carboxylase deficiency, HGN hyperglycinemia, DHPD dihydropyrimidine deficiency

a study conducted by Shawky et al. [5] at Ain Shams University, Egypt, in which 17 patients (43.5%) had consanguineous parents. Also, our results were higher than a study carried out in Iraq by Arif et al. [6], in which 174 (9.9%) neonates had positive consanguineous marriage and 132 (7.5%) of their patients had positive family history of either metabolic disorders or sudden unexplained death of siblings. In this study, the presentation day ranged from 3 to 12 days with a mean of 6.5 ± 0.7 days after-birth. This was consistent with Shawky et al. [5] who reported that all patients were normal at birth with no complications during delivery, and then they started to develop symptoms at an age ranged from 1 to 10 days with a mean of 3.4 ± 2.2 days.

In our study, the most common manifestation at the time of presentation was sepsis-like manifestations (poor suckling, found in 122 out of 200 cases (61%), followed by respiratory distress in 114 out of 200 cases (57%), then convulsions in 108 out of 200 cases (54%), and vomiting in 104 out of 200 cases (52%)). Our results were in agreement with Shawky et al. [5] and Clarke [8] who reported that sepsis-like symptoms were the most common presentation (26.5% and 15%), respectively. Also, Lunda et al., 2002, reported that the predominant symptoms in neonates suggesting the possibilty of metabolic disorders were convulsions and lethargy [9].

The prevalence of IEM in the current study was similar with Shawky et al. [5] and higher than that found in a study carried out by Selim et al. [10], an Iranian study by Pishva et al. [11], two studies by Elsobky and Elsayed [12] and Riyami et al. [13], an Indian one by Nagaraja et al. [14], an Iraqi one by Arif et al. [6], and two Chinese studies by Sun et al. [15] and Huang et al. [16] (Fig. 1).

Shawky et al. [5] showed that 13/40 (35.5%) suspected neonates were admitted to the El Mahalla Hospital NICU, Egypt, over 1-year duration with sepsis-like symptoms, convulsions, persistent metabolic acidosis, persistent vomiting, and previous sibling death of unidentified causes confirmed to have IEM.


Moreover, Pishva et al. [11] reported that the prevalence of IEM was 14%, which was lower than in our study (Fig. 2). Another study in Karachi by Wajner et al. [17] reported the prevalence of 25.8%. Moreover, several other studies, in Egypt by Elsobky and Elsayed [12], in Brazil by Coelho et al. [18], and in India by Nagaraja et al. [14], reported lower detection rate 6.5%, 3.17%, and 3.2%, respectively.


Additionally, a study done in Oman by Riyami et al. [13] found that 10.8% of their patients were diagnosed with IEMs in high-risk Omani neonates. Likewise, an Iraqi study by Arif et al. [6] with a total number of 1758 symptomatic Iraqi children from birth to early adolescence was analyzed for possible IEM; positive cases were 224/1758, with a rate of detection (12.7%) both of which were lower than in our study.

Table 8 The abnormal amino acids/acylcarnitines in dried blood spots and organic acids in urine of the different disease types in the studied cases

IEM Disease	No.	Abnormal amino acids/acylcarnitines in DBS			
		Amino acids/acylcarnitine	Concentration (µM)	Cut-off (μM)	Organic acid in urine
1. UCD	20	Arginine	124.7 ± 35.7 (99–142)	49	Not done
		 Citrulline 	98.4 ± 14.1 (83–126)	33	
		• Ornithine	625.8 ± 19.8 (602–654)	350	
2. MSUD	18	 Leucine-isoleucine 	361.9 ± 18.4 (318–378)	270	Not done
		• Valine	377.1 ± 43.5 (327–406)	198	Not done
3. FAOD	15	• C6-carnitine	$1.08 \pm 0.6 (1.1-1.2)$	< 0.16	Not done
		C8-carnitine	$1.30 \pm 0.9 (1.2 - 1.4)$	< 0.18	Not done
		C10-carnitine	$1.98 \pm 0.5 (1.8-2.1)$	< 0.26	Not done
		C12-carntine	1.76 ± 0.6 (1.7–1.9)	< 0.410	Not done
		C14-carnitine	$1.64 \pm 0.4 (1.6-1.7)$	< 0.413	Not done
		• C5-OH-carnitine	$1.92 \pm 0.3 \ (1.8-2.0)$	< 0.8	Not done
		C16-carnitine	$6.07 \pm 0.6 (5.9-6.2)$	< 5.06	Not done
		C18:1-carnitine	4.75 ± 2.9 (2.5–7.4)	< 3.50	Not done
4. THPN	15	 Phenylalanine 	161.6 ± 18.9 (143–182)	84	Not done
5. OA	15	• Propionic acidemia	$5.00 \pm 0.6 (4.6-5.8)$	4	↑3-Hydroxy-Propionic acid
		Glutaric acidemia	0.93	0.34	↑3-Hydroxy glutaric acid
		• β-ketothiolase Def.	_	_	†Tiglylglycine
		 Methylmalonic acid(C3) 	4.00 ± 1.3 (2.9–5.2)	4	↑Methyl-malonic acid
		• Methyl-crotonyl acidemia	8	1	↑Methyl-crotonyl acid
6. ST	4	• Tyrosine	648.5 ± 56.0 (589–714)	225	Not done
7. SG	3	• No	-	=	Not done
8. SMCD	1	• No	-	=	Not done
9. HGN	1	• Glycine	3500	717	Not done
10. DHDP	1	• No	_	_	Uracil and thiamine ↑

UCD urea cycle defect, MSUD maple syrup urine disease, FAOD fatty acid oxidation defect, THPN transient hyperphenylalaninemia, OA organic acidemia, ST suspected tyrosinemia, SG suspected galactosemia, SMCD suspected multiple carboxylase deficiency, HGN hyperglycinemia, DHPD di-hydro-pyrimidine deficiency





Amino acid disorder (AA) in our study was accounted as the most common disorder detected, and this was in accordance with Selim et al. [10]. Regarding the AA disorders, urea cycle disorders (UCD) was the most common type in our study, detected in 20/70 (28.5%) of diagnosed cases, with male predominance in 15/20 case (75%). This was in agreement with Shawky et al. [5] as UCD was the most common type with an incidence but with higher level than our study that was 53.8%, and 75% of the diagnosed cases were males. In Shawky et al.'s study [5], the most common IEM was UCD in 7/13, then MSUD in 2/13, followed by MMA and MCAD 1/13. Dissimilar, Gündüz et al. [4] found that UCD was detected only in six cases (11.8%), which were lower than in our study for both.

The second most common amino acid disease in our study was maple syrup urine disease (MSUD), which was detected in 18 cases (25.7%). Our results were higher than in Shawky et al. [5] who diagnose 2/13 (15.4%) cases with MSUD and Selim et al. [10] which was 7.4%. Similarly, Karam et al. [19] in Lebanon identified MSUD in 9.1%; in Fateen et al. [20] in Egypt, it was 1.2%; and Elsobky and Elsayed [12] reported that 10% of children with convulsions had MSUD. This can be explained by the larger number of patients in our study complaining from poor suckling and convulsions, and these presentations are considered as the common symptoms of MSUD.

Furthermore, in our study, organic acidemia was presented in 15/70cases (21.4%), which was higher than in Shawky et al. [5] who detect organic acidemia in 3/40 (7.5%) and in Elsobky and Elsayed [12] who reported organic acidemia in 1.07%.

In our study, one case was diagnosed as B-ketothiolase deficiency; this case was presented on the 1st day after

birth with persistent vomiting, convulsion, metabolic acidosis, and hypoglycemia. This patient had one sister with the same disease diagnosed after birth with increased tiglylglycine in urine. In our study, fatty acid oxidation defect was presented in 15/70 cases (21.4 %). This was higher than Riyami et al. [13] in Oman, who detect FAOD in (16%) of cases; Shawky et al. [5] who found FAOD in 1/13 (7.6%); in Selim et al. [10] who found FAOD in 3.4% of patients; and in Arif et al.'s study [6] in Iraq (1.1%).

Our results were lower than that of Vargas et al. [7] who reported that FAOD was detected in 19 patients (28%). These higher results in their study can be explained by their selection criteria which were based on selection of patients with FAOD manifestations only.

In our study, galactosemia was suspected in 3/200 (1.5%) cases. Our results were lower than a study by Fateen et al. [20], who detected galactosemia in (2.5%) of cases. As well, a study by Shawky et al. [5] detected galactosemia in (7.7%) and in a study by Arif et al. [6], who detected galactosemia in 31/1758 (1.76%) of cases. This difference might be explained by that more neonates in their studies presented with clinically suspicious galactosemia and have facilities to do enzymatic assay for galactosemia that was not available in our hospital. Also, they included larger number of patients for longer time.

Conclusion

From this descriptive study, we concluded that IEM disorders are not rare disease in high-risk neonates with attentions to consanguinity which is a common tradition in our country. Regarding the metabolic disorders, manifestation presented in most cases, i.e., sepsis-like manifestations. These manifestations are common, and many

physicians misdiagnose them as they are unaware about these disorders. IEMs represented a significant cause of sick neonate's admission to NICU, and it should be considered as a differential diagnosis for any sick neonate. Most IEMs are inherited in an autosomal recessive pattern, so its incidence increases with positive consanguinity. The delay in diagnosis of IEM (due to lack of facilities) leads to high morbidity and mortality, so early detection and early intervention to the neonates at risk of IEMs before the onset of symptoms can prevent or, at least, reduce serious neurological and developmental squeal.

Acknowledgements

We acknowledge the medical staff of Neonatal Intensive Care Unit, Assiut University Children Hospital, and staff member of Genetics Unit at Assiut Children Hospital and Ain Shams Genetic Unit. It was not possible to complete this work without the help and approval of the neonates' caregivers.

Authors' contributions

SMK was responsible for the conception and design of the study, acquisition of data, analysis and interpretation of data, critical revision of the submitted protocol for important intellectual content, statistical analysis, and supervision. MME was responsible for the conception and design of the study, analysis and interpretation of data, critical revision of the submitted protocol for important intellectual content, statistical analysis, and supervision. NHR was responsible for the conception and design of the study, analysis and interpretation of data, critical revision of the submitted protocol for important intellectual content, statistical analysis, and supervision. AMA was responsible for the conception and design of the study, analysis and interpretation of data, technical, material support, and supervision. All authors had read and approved the final manuscript.

Funding

This study was funded by Faculty of Medicine, Assiut University, for detection of metabolic disorders in neonates admitted at Assiut University Children Hospital.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was approved by the corresponding Ethical Review Board at Assiut University (N: 1050, 14/07/2015), and written informed consent was taken from patients' parents.

The work has been performed in accordance with Helsinki Declaration consent for publication.

The authors agree for the publication of identifying images or other personal or clinical details of the participants.

Consent for publication

Consent for publication data was taken from patients' parents, and they agree for the publication.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Pediatrics, Assiut University, Assiut University Children Hospital, Assiut 71515, Egypt. ²Clinical Pathology Department, Assiut University, Assiut University Hospital, Assiut 71515, Egypt.

Received: 5 June 2019 Accepted: 9 October 2019 Published online: 28 November 2019

References

- Ezgu F. Inborn errors of metabolism. Advances in clinical chemistry. 73: Elsevier; 2016. p. 195-250.
- Campeau PM, Scriver CR, Mitchell JJ (2008) A 25-year longitudinal analysis
 of treatment efficacy in inborn errors of metabolism. Molecular genetics
 and metabolism. 95(1-2):11–16
- Cloherty JP, Eichenwald EC, Stark AR (2008) Manual of neonatal care: Lippincott Williams & Wilkins
- Gündüz M, Ünal S, Okur İ, Ayranci-Sucakli I, Güzel F, Koç N (2015) Neonates with inborn errors of metabolism: spectrum and short-term outcomes at a tertiary care hospital. The Turkish journal of pediatrics. 57(1):45
- Shawky RM, Abd-El Khalek HS, Elakhdar SE (2015) Selective screening in neonates suspected to have inborn errors of metabolism. Egyptian Journal of Medical Human Genetics. 16(2):165–171
- Arif A, Thejeal RF, Farhan A (2016) Inborn errors of metabolism status in Iraq. IOSR J Pharm Biol Sci. 11:58–62
- Vargas CR, Ribas GS, da Silva JM, Sitta A, Deon M, de Moura CD et al (2018) Selective Screening of fatty acids oxidation defects and organic acidemias by liquid chromatography/tandem mass spectrometry acylcarnitine analysis in Brazilian patients. Archives of medical research. 49(3):205–212
- Clarke S (2002) Tandem mass spectrometry: the tool of choice for diagnosing inborn errors of metabolism? British journal of biomedical science. 59(1):42–46
- Lund A, Christensen E, Skovby F (2002) Diagnosis and acute treatment of inborn metabolic diseases in infants. Ugeskrift for Laeger. 164(48):5613–5619
- Selim LA, Hassan SA-H, Salem F, Orabi A, Hassan FA, El-Mougy F et al (2014) Selective screening for inborn errors of metabolism by tandem mass spectrometry in Egyptian children: a 5 year report. Clinical biochemistry. 47(9):823–828
- Pishva N, Mirzaee A, Karamizade Z, Pourarian S, Hemmati F, Razvi M et al (2015) Selective screening of 650 high risk Iranian patients for detection of inborn error of metabolism. Iranian Journal of Neonatology JJN. 5(4):11–14
- 12. Elsobky E, Elsayed SM (2004) Extended metabolic screen in sick neonates and children. Egypt J Med Hum Genet. 5(2):1–7
- Al Riyami S, Al Maney M, Joshi SN, Bayoumi R (2012) Detection of inborn errors of metabolism using tandem mass spectrometry among high-risk Omani patients. Oman medical journal. 27(6):482
- 14. Nagaraja D, Mamatha SN, De T, Christopher R (2010) Screening for inborn errors of metabolism using automated electrospray tandem mass spectrometry: study in high-risk Indian population. Clinical biochemistry.
- Sun W, Wang Y, Yang Y, Wang J, Cao Y, Luo F et al (2011) The screening of inborn errors of metabolism in sick Chinese infants by tandem mass spectrometry and gas chromatography/mass spectrometry. Clinica Chimica Acta. 412(13-14):1270–1274
- Huang X, Yang L, Tong F, Yang R, Zhao Z (2012) Screening for inborn errors of metabolism in high-risk children: a 3-year pilot study in Zhejiang Province. China. BMC pediatrics. 12(1):18
- Wajner M, de Moura CD, Ingrassia R, de Oliveira AB, Busanello ENB, Raymond K et al (2009) Selective screening for organic acidemias by urine organic acid GC–MS analysis in Brazil: Fifteen-year experience. Clinica Chimica Acta. 400(1-2):77–81
- Coelho JC, Wajner M, Burin MG, Vargas C, Giugliani R (1997) Selective screening of 10,000 high-risk Brazilian patients for the detection of inborn errors of metabolism. European journal of pediatrics. 156(8):650–654
- Karam PE, Habbal M-Z, Mikati MA, Zaatari GE, Cortas NK, Daher RT (2013) Diagnostic challenges of aminoacidopathies and organic acidemias in a developing country: a twelve-year experience. Clinical biochemistry. 46(18):1787–1792
- Fateen EM, Ibrahim M, Abdallah Z (2014) Fifteen years experience: Egyptian metabolic lab. Egyptian Journal of Medical Human Genetics. 15(4):379–385

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.